Gene therapy study for typical Canavan disease in children
Treatments studied
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This early-phase trial tests a gene therapy medicine (delivered by a one-time infusion) for children with typical Canavan disease. It aims to improve safety and help evaluate whether the treatment may benefit children over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- A neurologist must confirm you have typical Canavan disease
- You must be able to get a parent/guardian consent and attend required follow-up visits
- Your age must match the study group: under 15 months, 15–36 months, or 36–60 months
- You likely must not have major health problems that raise surgery risk or disrupt study visits
- You must not have had severe allergic reactions, gene therapy, or another study medicine in the last 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests an AAV9 gene therapy to treat Canavan disease. It aims to improve disease-related findings in children whose genetic test confirms ASPA gene changes.
This trial tests a gene therapy for people with a specific mutation (S295L) in the SLC6A1 gene, which causes a neurodevelopmental disorder. The therapy aims to correct the genetic issue, and participants will be monitored closely for safety and effectiveness.
This early-phase study tests a gene therapy meant to treat people who have IGHMBP2 gene changes. It aims to improve the way the nervous system works and to see if the treatment is safe, especially in young children.
This trial tests a new gene therapy for Parkinson's disease. The therapy is delivered directly into the brain during a surgical procedure, with the goal of improving motor symptoms and reducing 'off' time.
This early-stage trial tests VGN-R09b, a gene therapy, given to children with AADC deficiency who are not doing well on standard medicines. It aims to improve symptoms and quality of life by addressing the underlying cause of AADC deficiency.
This trial tests a one-time gene therapy injection for children with Sanfilippo syndrome type B (MPS IIIB), a condition that affects the brain and development. The goal is to see if adding a healthy gene can slow or stop the disease.
Hear when a new Canavan Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.